BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30

• 

  Job Trends

  EXCLUSIVE: Cellular Biomedicine Group Ready to Hire After Snapping Up Cancer Vaccine

  June 24, 2015

   · 

  4 min read
• 

  Drug Development

  AbbVie’s Viekira Pak Clears Another Hurdle, 100% HCV-1b Clearance Rate in Phase III Trial

  June 24, 2015

   · 

  3 min read
• CureVac Announces Study Publication In Molecular Therapy Demonstrating Wide-Ranging Benefits Of Sequence-Optimized, Unmodified mRNAs

  June 24, 2015

   · 

  4 min read
• Business

  Guardant Health Partners With National Cancer Institute On First Ever Prospective Study To Implement cfDNA Genomic Profiling For Non-Small Cell Lung Cancer

  June 24, 2015

   · 

  5 min read
• Drug Development

  Perle Bioscience Release: Insulin Independence Revolutionary Phase 3 Trial

  June 24, 2015

   · 

  2 min read
• Calcivis Raises £4.5m To Drive Development Of The Calcivis Caries Activity Imaging System Through To Commercialisation

  June 24, 2015

   · 

  4 min read
• Drug Development

  Celator Pharmaceuticals, Inc. Announces Positive Induction Response Results From Phase 3 Study Of CPX-351 In Patients With High-Risk (Secondary) Acute Myeloid Leukemia

  June 24, 2015

   · 

  8 min read
• Drug Development

  Novo Nordisk A/S Release: In A Phase 3 Trial, Novoeight(Antihemophilic Factor [Recombinant]) Provided Long-Term Efficacy And Safety In The Prophylaxis And Treatment Of Bleeds In People With Hemophilia A

  June 24, 2015

   · 

  5 min read
• Drug Development

  Transition Therapeutics Inc. Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer’s Disease

  June 24, 2015

   · 

  2 min read
• Viratherapeutics Raises €3.6 Million In The First Closing Of A Series A Financing Round To Advance Its Novel Oncolytic Virus Platform

  June 24, 2015

   · 

  6 min read